Radiation Oncology

DOREMY: 36 Gy preoperative RT yields excellent local control in myxoid liposarcoma

This phase 2 single-arm trial delivered 36 Gy preoperative RT followed by resection in 90 adults with localized, translocation-confirmed myxoid liposarcoma. At median 66 months follow-up, 5-year local recurrence-free survival was 97.4%, with 5-year OS 88.5% and PFS 81.0%. Wound complications occurred in 21% (16% required intervention) and late grade ≥2 toxic effects in 15% (3% grade 3). Authors conclude the reduced-dose regimen has favorable long-term control and toxicity and may be adopted via shared decision-making for eligible patients. 1

Protocol: systematic review of PROM test-retest reliability in cancer

This protocol outlines a COSMIN-based systematic review of test-retest reliability for patient-reported outcome measures in adult oncology. Planned methods include searches of five databases and supplementary sources, independent dual review, and narrative synthesis due to expected heterogeneity. The review will focus on retest intervals, patient stability assessment, sample size, and statistical analysis to guide PROM validation in cancer populations. 2

ADT + RT reduces cancer-specific and all-cause mortality in older locally-advanced prostate cancer

In a SEER‑Medicare emulation (n=5,494; 3,378 received ADT+RT), ADT+RT was associated with lower cancer-specific mortality (HR 0.61) and lower all-cause mortality (HR 0.84). Results were consistent across frailty, stage, Gleason score, and PSA after sIPW adjustment with median follow-up 64 months. Higher claims-based frailty reduced the likelihood of receiving ADT+RT (adjusted OR 0.81 per unit CFI), despite preserved cancer-specific benefit. 3